FDA Testimony - Implementation of GDUFA (2!4!16)
Transcript of FDA Testimony - Implementation of GDUFA (2!4!16)
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
1/20
, ..,
..
4, 2016
, , . , ()
( ), (). 2012 ().
. , 88%
, .. $1.68
2005 2014.
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
2/20
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
3/20
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
4/20
,
. 2012.
, $300 . , ,
( ) . ,
, , . , ,
()
, , , , . , .
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
5/20
,
.
0% ,
1, 2012,
201. 1, 2012, 266 13 .
5 , , 4% % .
,
, .
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
6/20
.
, ,
, , (..,
( ) ).
,
.
, .
.
, , . .
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
7/20
, 2,500
2013 2014 . ,
2013 2014 . , , (),
2013 2014 .
, 2015 15
. .
. ,
, ,
.
, ,
. 2015 .
2015.
201 15 ,
.
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
8/20
. ,
.
, , .
() 12
.
,
2015.
.
, ,
.
. , 2015,
15 .
. ,
, .
, .
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
9/20
A ()
()
()
()
()
() ()
()
()
; , ;
; ;
.
15% . A
. 3
200 . 2015,
() , .
, B
,
,
, A ,
, A A .
. B 2012,
,
, . A
.
2017.
A A. A
. ,
A A 60% 6
10 .
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
10/20
A . C
A
. A 2015 70% 4
. A C 9, .
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
11/20
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
12/20
,
, ,
, ,
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
13/20
, , .
.
, .
,
. . . 0,
,00 .
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
14/20
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
15/20
, .
.
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
16/20
,
( )
, ,
,
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
17/20
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
18/20
. 16 , , 23%. 5%. .
, .
. ,
. , . . , $34.
. , , .
, . . ()
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
19/20
.
.
.
, ,
. ,
,
. ,
, .
.
.
.
. .
.
.
1. (/
////22505.)
2.
.
3.
.
, .
.
.
4.
.
5. , ,
.
6. / (//////
/404.)
7. (///
//4134.)
8. (///
/256662.)
9. (///3233.)
10
-
7/25/2019 FDA Testimony - Implementation of GDUFA (2!4!16)
20/20
10. (//../.)
(//../////
.)
201 (///2.)
201 (///21.)
201 (///.)
201 (///0.)
(///.)